Share This Author
Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study
- B. Kahan
- MedicineThe Lancet
- 15 July 2000
Maintenance Immunosuppression with Target-of-Rapamycin Inhibitors is Associated with a Reduced Incidence of De Novo Malignancies
- H. Kauffman, W. Cherikh, Yulin Cheng, D. Hanto, B. Kahan
- Medicine, BiologyTransplantation
- 15 October 2005
Maintenance immunosuppression with the TOR inhibitor drugs, sirolimus and everolimus, is associated with a significantly reduced risk of developing any posttransplant de novo malignancy and nonskin solid malignancies.
Clinical Pharmacokinetics of Sirolimus
Despite the fixed dosage regimens used in these pivotal trials, pharmacokinetic and clinical data show that sirolimus is a critical-dose drug requiring therapeutic drug monitoring to minimise drug-related toxicities and maximise efficacy.
Everolimus versus Mycophenolate Mofetil in the Prevention of Rejection in De Novo Renal Transplant Recipients: A 3-Year Randomized, Multicenter, Phase III Study
As part of triple-drug immunosuppression, everolimus (1.5 or 3 mg/day) was as efficacious as MMF, although the side-effect profile featured increased adverse events.
Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation.
Thymoglobulin was found to be superior to Atgam in reversing acute rejection and preventing recurrent rejection after therapy in renal transplant recipients.
Pharmacokinetics of Sirolimus in Stable Renal Transplant Patients after Multiple Oral Dose Administration
Preliminary analysis suggested that values for the pharmacokinetic parameters of sirolimus vary among races (black versus nonblack) but not among genders, and linear dose proportionality was suggested.
Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post‐transplant year: Pharmacokinetics, exposure‐response relationships, and influence on cyclosporine
- J. Kovarik, B. Kahan, C. Rordorf
- Medicine, BiologyClinical pharmacology and therapeutics
- 1 January 2001
The steady‐state pharmacokinetics of everolimus and cyclosporine when coadministered in de novo kidney allograft recipients during the first year after transplantation are characterized.
Lake Louise Consensus Conference on Cyclosporin Monitoring in Organ Transplantation: Report of the Consensus Panel
Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation
This association suggests that improved cyclosporine pharmacokinetic monitoring may aid in improving outcome after kidney transplantation, and an equation is described to provide initial oral dose prediction.
Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect…
Prophylactic basiliximab therapy is well tolerated, has an adverse event profile comparable to placebo, and significantly reduces the number of acute rejection episodes in renal allograft patients within the first year after transplantation.